Company Filing History:
Years Active: 2002
Title: David M Sabatini: Pioneering Researcher in Mammalian Proteins
Introduction: David M. Sabatini is a distinguished inventor based in Baltimore, MD, well-known for his significant contributions to the field of mammalian proteins. With a total of two patents to his name, his work primarily focuses on the interactions of proteins in a rapamycin-dependent manner, which has crucial implications in pharmacology and biological research.
Latest Patents: Sabatini's latest patents pertain to the discovery of mammalian proteins that bind to FKBP12 in the presence of rapamycin. The protein complex he identified consists of 245 kDa and 35 kDa components, designated RAFT1 and RAFT2. This interaction demonstrates pharmacological characteristics expected from the observed in vivo effects of rapamycin, manifesting at low nanomolar concentrations and being competed by excess FK506. His research also unveiled that sequences derived from the 245 kDa RAFT1 exhibit striking homologies to the yeast TOR genes, originally connected to rapamycin resistance in yeast. A cDNA for RAFT1 further corroborated his findings by encoding a 289 kDa protein that shares considerable identity with TOR2 and TOR1.
Career Highlights: David M. Sabatini's innovative work is affiliated with The Johns Hopkins University, where he continues to push the boundaries of biological research. His commitment to the scientific community is evident through his extensive research in protein interactions and their effects on cellular processes.
Collaborations: Throughout his career, Sabatini has collaborated with renowned colleagues such as Hediye Erdjument-Bromage and Mary Lui. These partnerships have not only expanded the scope of his research but have also enriched the scientific discourse in the field of molecular biology.
Conclusion: David M. Sabatini stands out as a pivotal figure in the landscape of scientific research, particularly in the study of mammalian proteins. His innovations and patents are invaluable to the ongoing exploration of protein interactions and their implications for pharmacological applications. Through his work at The Johns Hopkins University, he continues to contribute significantly to the development of innovative solutions in the life sciences.